Skip to main content

Table 2 Antitumor effectiveness of triple mIL-12 gene electrotransfer alone or combined with irradiation on SA-1 sarcoma

From: Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma

Therapeutic group

N

DT (days; AM ± SE)*

GD (days; AM ± SE)**

Cures(%; n)

SC resistance (n)#

Control

10

3.4 ± 0.4

-

0

 

3× EP

10

6.0 ± 1.0

2.7 ± 1.0

0

 

3× dsRed

10

3.1 ± 0.3

−0.3 ± 0.3

0

 

3× EGT dsRed

12

6.8 ± 0.8

3.4 ± 0.8

8.3 (1/12)

1/1

3× mIL-12

13

5.2 ± 1.3

1.9 ± 1.3

0

 

3× EGT mIL-12

14

17.7 ± 5.4

14.3 ± 5.4

50.0 (7/14)

7/7

IR 10 Gy

10

8.1 ± 1.5

4.8 ± 1.5

0

 

3× EP + IR

11

13.1 ± 1.9

9.7 ± 1.9

27.3 (3/11)

3/3

3× dsRed + IR

12

9.9 ± 1.8

6.5 ± 1.8

16.7 (2/12)

2/2

3× EGT dsRed + IR

12

25.7 ± 4.8 ‡§

22.3 ± 4.8

25.0 (3/12)

3/3

3× mIL-12 + IR

14

10.2 ± 1.7

6.9 ± 1.7

7.1 (1/14)

1/1

3× EGT mIL-12 + IR

15

43.1 ± 28.8 ‡§

39.8 ± 28.8

86.7 (13/15)

13/13

  1. Therapeutic groups: 10 Gy single dose irradiation (IR), triple electric pulse application alone (3× EP) or combined with irradiation (3× EP + IR), triple intratumoral injection of plasmid DNA coding for mIL-12 or dsRed alone (3× mIL-12, 3x dsRed) or combined with irradiation (3× mIL-12 + IR, 3× dsRed + IR), triple mIL-12 or dsRed gene electrotransfer alone (3× EGT mIL-12, 3× EGT dsRed) or combined with irradiation (3× EGT mIL-12 + IR, 3× EGT dsRed + IR).
  2. N - Number of all mice in the group.
  3. * - Tumor doubling time - only mice with tumors were included in calculation.
  4. ** - Tumor growth delay - only mice with tumors were included in calculation.
  5.  - Cures were determined 100 days after the treatment.
  6. # - Resistance to secondary challenge – number of cured mice that were resistant to secondary challenge is shown.
  7.  - Statistical significant difference compared to control group (p < 0.05).
  8. § - Statistical significant difference compared to IR 10 Gy (p < 0.05)